Background Fidarestat, an aldose reductase (AR) inhibitor, displays promise for the treatment of diabetic neuropathy, although the underlying mechanism of action remains unclear. Histone modification, especially histone acetylation, has been implicated in the pathogenesis of diabetes and its complications.
Introduction
Ample evidence has demonstrated that uncorrected type 2 diabetes and obesity are associated with cardiac hypertrophy and compromised ventricular function [1] [2] [3] . Several theories have been postulated for diabetes/ obesity-induced cardiac dysfunction, with impaired signaling of the obesity gene product leptin being a rather unique one [4] . Type 2 diabetes and obesity may be initiated by abnormal expression of leptin or the leptin receptor, which results in leptin deficiency (such as ob/ob mice) or hyperleptinemia (such as db/db mice). Both hypo-and hyperleptinemia may cause obesity-related cardiac dysfunction [4] [5] [6] . Leptin deficiency-induced cardiac defect can be reconciled following replenishment of recombinant leptin [5, 7] , indicating an essential role of leptin signaling in the maintenance of heart function. Unfortunately, since the majority of obese individuals possess higher rather than lower circulating leptin levels, leptin deficiency (ob/ob mice) may not be the best representative model for the experimental study of human obesity. Although cardiac contractile dysfunction has been shown in the leptin-surplus db/db mice [8] , no effective therapeutic regimen is available for the compromised cardiac function under such a hyperleptinemic condition. Recently, accumulating evidence indicated a role of the polyol pathway in the onset of diabetic cardiovascular complications [9] and systemic inflammatory response-induced cardiomyopathy [10] . The polyol pathway mainly involves two enzymes, namely aldose reductase (AR) and sorbitol dehydrogenase (SDH). AR catalyzes reduction of glucose to sorbitol, which is then converted to fructose by SDH using NAD þ as a cofactor [11] . Fidarestat, a novel inhibitor of AR, displays promise for the treatment of peripheral diabetic polyneuropathy [9] . Nonetheless, little is known regarding the effect of fidarestat on other complications of diabetes or obesity. Therefore, this study was designed to examine the impact of fidarestat on cardiomyocyte dysfunction in db/db diabetic obesity. Since histone modification, especially histone acetylation, has been implicated in the pathogenesis of diabetic complications [12] , we further tested the effect, if any, of the NAD-dependent histone deacetylase silent information regulator 2 (Sir2) inhibitor splitomicin [13, 14] on db/db cardiomyocyte contractile function and fidarestat-induced effect. Sir2 gene transfer has been shown to protect cardiomyocytes from apoptosis, whereas Sir2 inhibitors may promote cell death [15, 16] , indicating a possible role of Sir2 in the regulation of cardiomyocyte survival and cardiac function.
Materials and methods
Experimental animals and plasma measurement The experimental procedures described in this study were approved by the University of Wyoming (Laramie, Wyoming, USA). In brief, male homozygous B6.Cg-m þ/þ Lepr db /J (db/db) mice were obtained from the Jackson Laboratory (Bar Harbor, Maine, USA) at 3 weeks of age and were housed within the School of Pharmacy Animal Facility with free access to food and water until 12 weeks of age. Age-and gender-matched wild-type C57BL/6J mice were used as lean controls. Systolic and diastolic blood pressures were examined with a semi-automated, amplified tail-cuff device (IITC Inc., Woodland Hills, California, USA). Blood glucose was monitored with a glucometer (Accu-ChekII, model 792; Boehringer Mannheim Diagnostics, Indianapolis, Indiana, USA). Plasma leptin and insulin levels were determined using a mouse leptin enzyme-linked immunosorbent assay (ELISA) kit and a mouse insulin ELISA kit (LINCO Research Inc., St. Charles, Missouri, USA), respectively. Plasma triglyceride and cholesterol levels were measured using assay kits from Diagnostic Chemicals (Oxford, Connecticut, USA).
Isolation of mouse left ventricular cardiomyocytes
Cardiomyocytes were enzymatically isolated as described previously [5] . In brief, hearts were removed and perfused with oxygenated (5% CO 2 /95% O 2 ) Krebs-Henseleit bicarbonate (KHB) buffer containing (in mmol/l) 118 NaCl, 4. stimulated with supra-threshold voltage and at a frequency of 0.5 Hz using a pair of platinum wires placed on the opposite sides of the chamber connected to a FHC stimulator (Brunswick, New England, USA). The myocyte being studied was displayed on the computer monitor using an IonOptix MyoCam camera, which rapidly scans the imaged area at every 8.3 ms such that the amplitude and velocity of shortening/re-lengthening was recorded with good fidelity. The soft-edge software from IonOptix was used to capture changes in cell length during contraction [5] . Cardiomyocytes from db/db diabetic obese and C57BL/6J mice were incubated with fidarestat (0.1-10 mmol/l) for 60 min in a serum-free defined medium consisting of Medium 199 (Sigma, St. Louis, Missouri, USA) with Earle's salts containing HEPES (25 mmol/l) and NaHCO 3 (25 mmol/l), supplemented with albumin (2 mg/ml), L-carnitine (2 mmol/l), creatine(5 mmol/l), taurine (5 mmol/l), insulin(100 nmol/l), glucose (11.1 mmol/l), penicillin (100 U/ml), streptomycin (100 mg/ml) and gentamicin (5 mg/ml). In some studies, myocytes were incubated with the Sir2 inhibitor splitomicin (20 mmol/l) for 30 min prior to the fidarestat application.
Intracellular Ca 2þ fluorescence measurement A cohort of myocytes was loaded with fura-2/AM (0.5 mmol/l) for 15 min, and fluorescence intensity was measured with a dual-excitation fluorescence photomultiplier system (IonOptix) [5] . Myocytes were placed on an inverted Olympus microscope and imaged through a Fluor 40Â oil objective. Cells were exposed to light emitted by a 75 W mercury lamp and passed through either a 360 nm or a 380 nm filter. Myocytes were stimulated to contract at 0.5 Hz. Fluorescence emissions were detected between 480 and 520 nm by a photomultiplier tube after cells were first illuminated at 360 nm for 0.5 s and then at 380 nm for the duration of our recording protocol (333-Hz sampling rate). The 360-nm excitation scan was repeated at the end of the protocol, and qualitative changes in intracellular Ca 2þ concentration were inferred from the ratio of the fura-2 fluorescence intensity (FFI) at two wavelengths.
Intracellular fluorescence measurement of superoxide (O 2
S ) Intracellular superoxide levels were measured by changes in fluorescence intensity that resulted from intracellular probe oxidation, according the previously described method [5] . Following a 60 min treatment with fidarestat (0.1-10 mmol/l), isolated cardiomyocytes were loaded with 5 mmol/l dihydroethidium (DHE) (Molecular Probes, Eugene, Oregon, USA) for 30 min at 378C and were rinsed with phosphate-buffered saline (PBS) buffer. Cells were sampled randomly using an Olympus BX-51 microscope equipped with an Olympus MagnaFire SP digital camera and ImagePro image analysis software (Media Cybernetics, Silver Spring, Maryland, USA).
Fluorescence was background subtracted and calibrated with InSpeck microspheres (Molecular Probes). More than 150 cells per treatment group were evaluated using the grid crossing method for cell selection in more than 15 visual fields per experiment.
Western blot analysis of Sir2, IkB and phosphorylated IkB Following a 4-h incubation with fidarestat and splitomicin, cardiomyocytes were collected and sonicated in a lysis buffer containing 20 mmol/l Tris (pH 7.4), 150 mmol/l NaCl, 1 mmol/l EDTA, 1 mmol/l EGTA, 1% Triton, 0.1% sodium dodecyl sulfate (SDS) and protease inhibitor cocktail. Equal amounts of protein lysates (50 mg/lane) were separated on 7% (Sir2) and 15% [inhibitor of kB (IkB) and phosphorylated IkB] SDS-polyacrylamide gels in a minigel apparatus (Mini-PROTEAN II; Bio-Rad, Hercules, California, USA) and transferred to nitrocellulose membranes (0.2 mm). The membranes were blocked in 5% (w/v) nonfat milk in Tris-buffered saline-Tween-20 (TBS-T) buffer, and then incubated with anti-Sir2 (1 : 1000), anti-IkB (1 : 1000), antiphosphorylated IkB (1 : 1000) and anti-bactin (1 : 8000) antibodies at 48C overnight. Anti-Sir2 antibody was purchased from Upstate Cell Signaling (Charlottesville, Virginia, USA). All other antibodies were purchased from Cell Signaling Technology (Beverly, Massachusetts, USA). After incubation with primary antibody, blots were incubated with an anti-rabbit IgG horseradish peroxidase (HRP)-linked antibody at a dilution of 1 : 5000 for 100 min at room temperature. Immunoreactive bands were detected using the Super Signal West Dura Extended Duration Substrate (Pierce, Milwaukee, Wisconsin, USA). The intensity of bands were measured with a scanning densitometer (Model GS-800; Bio-Rad) coupled with BioRad PC analysis software. For all western blot analysis experiments, b-actin was used as an internal loading control.
Statistical analysis
Data were shown as mean AE SEM. Differences were evaluated by analysis of variance (ANOVA) followed by the Tukey post-hoc analysis. Statistical significance was considered to be P < 0.05.
Results

General features of experimental animals
The general biometric features of the 12-week-old male lean and db/db obese mice are shown in Table 1 . The db/ db mice were overtly obese compared with their lean controls. The body, heart and liver weights were all significantly heavier than those from the age-matched lean control group. Systolic pressure, plasma levels of glucose, insulin, leptin, cholesterol and triglyceride were significantly higher in db/db mice compared with those from the lean controls (Table 1) . Following an acute intraperitoneal glucose (2 g/kg) injection, the postchallenge glucose level remained elevated up to 120 min in db/db mice compared with that from the lean controls (data not shown), indicating existence of glucose intolerance in db/db obese mice.
Effect of fidarestat treatment on cell shortening/relengthening in lean control and db/db mice Cardiomyocytes from db/db mice displayed a larger crosssectional area, and decreased peak shortening (PS) and maximal velocity of shortening/re-lengthening (AEdL/dt), prolonged time-to-90% re-lengthening (TR 90 ) and normal time-to-peak shortening (TPS) compared with myocytes from lean mice (Fig. 1) . Consistent with the mechanical characteristics, myocytes from db/db mouse hearts displayed reduced fura-fluorescence intensity change (DFFI), an indication of electrically stimulated increase in intracellular Ca 2þ , associated with a slowed intracellular Ca 2þ decay rate and normal resting intracellular Ca 2þ level (basal fura-2 fluorescence intensity) (Fig. 2) . Interestingly, these mechanical and intracellular Ca 2þ aberrations in db/db mouse myocytes were significantly improved following incubation with fidarestat for 60 min in vitro. Fidarestat restored the reduction in PS, AEdL/dt (at 10 mmol/l) and DFFI (at 1 mmol/l or higher), prolongation in TR 90 and intracellular Ca 2þ decay rate (at 0.1 mmol/l or higher) in db/db mouse cardiomyocytes. The enlarged cross-sectional area of db/db mouse myocytes was not affected by fidarestat at the concentrations tested. Fidarestat did not overtly affect cell mechanics in cardiomyocytes from lean control mice with the exception of prolonged TR 90 at the highest fidarestat concentration tested (Fig. 1f) .
Effect of fidarestat treatment in the presence of the Sir2 inhibitor splitomicin To examine the possible signaling mechanism responsible for the fidarestat-elicited protective effect against cardiomyocyte dysfunction in db/db mice, we repeated the in-vitro fidarestat experiment in the presence of the silencing factor Sir2 inhibitor splitomicin (20 mmol/l). Interestingly, the beneficial effects of fidarestat on cardiomyocyte dysfunction in db/db mice were nullified by co-incubation with splitomicin, with the exception of intracellular Ca 2þ decay rate and TR 90 (Fig. 3) .
Effect of fidarestat on intracellular superoxide (O 2 S ) generation To explore the mechanism of action behind the compromised cardiac contractile function in db/db mouse myocytes, we measured superoxide (O 2 À ) levels in cardiomyocytes using the DHE fluorescence probe. Myocytes from db/db mice showed significantly higher superoxide levels compared with myocytes from the lean controls. Consistent with our mechanical observations shown in Figs 1 and 2 , the 60-min in-vitro fidarestat treatment nullified the enhanced superoxide levels in myocytes from db/db mice. Fidarestat itself did not significantly affect DHE fluorescent intensity in lean control myocytes (Fig. 4) .
Changes of protein expression in Sir2, IkB and phosphorylated IkB
In an effort to examine the cell signaling pathways involved in compromised cardiac contractile function in db/db mouse myocytes and the beneficial effect of fidarestat, we evaluated expression of Sir2, IkB and AR inhibitor benefits heart function via Sir2 Dong and Ren 2141 Fig. 1 Contractile properties of myocytes from C57BL lean control and db/db mouse hearts treated with or without fidarestat (0.1, 1 and 10 mmol/l) for 60 min. (a) Representative traces depicting myocyte shortening of cells from lean control, db/db myocytes and db/db cells treated with 10 mmol/l fidarestat; (b) cross-sectional area; (c) peak shortening (PS, normalized to cell length); (d) maximal velocity of shortening (þdL/dt) and re-lengthening (ÀdL/dt); (e) time-to-PS (TPS); and (f) time-to-90% re-lengthening (TR 90 ). Mean AE SEM, n ¼ 30-50 cells per group; Ã P < 0.05 versus lean control group, # phosphorylated IkB using western blots. Protein expression of Sir2 was reduced in db/db mouse hearts. The ratio between the phosphorylated IkB and total IkB was increased in db/db mice, suggesting diminished inhibition of the transcription factor NFkB or NFkB activation in db/db mice. Fidarestat treatment restored the ratio between phosphorylated IkB and IkB, the effect of which was abolished by the Sir2 inhibitor splitomicin (Fig. 5) .
Discussion
The major finding of our present study is that the AR inhibitor fidarestat improved cardiomyocyte contractile dysfunction of db/db diabetic obese mouse cardiomyocytes through, at least in part, a Sir2-dependent pathway. Our results revealed major mechanical abnormalities of cardiomyocytes from db/db diabetic obese mice, including depressed PS, reduced AEdL/dt and prolonged TR 90 . In addition, intracellular Ca 2þ fluorescence measurement demonstrated decreased DFFI and slowed intracellular Ca 2þ decay in db/db mouse myocytes, suggesting compromised electrically stimulated intracellular Ca 2þ release and extrusion. These mechanical deficits were accompanied with a 13.7-fold increase in plasma leptin levels and an approximately 100% rise in plasma cholesterol as well as triglyceride levels in db/db mice.
Cardiomyocyte dysfunction along with increased plasma leptin levels seems to indicate that leptin plays an important role in mechanical deficits in db/db obesity, which is consistent with our earlier observation that leptin exhibits negative inotropic effects on myocyte contraction and intracellular Ca 2þ release [17] . Interestingly, the mechanical dysfunction in db/db mouse myocytes was improved by in-vitro treatment with fidarestat, a novel AR inhibitor showing promise in the treatment of peripheral diabetic polyneuropathy [9] . Our data indicated that the AR inhibitor may have some promise in the management of diabetes and/or obesity-associated heart dysfunction.
As a major enzyme in the polyol pathway, AR catalyzes reduction of glucose to sorbitol, the process of which is believed to contribute to the pathogenesis of diabetic cardiovascular complications [9, 18] . Normally, AR has a low affinity for glucose in the nondiabetic state; however, its affinity for glucose is dramatically increased in the diabetic or high glucose state, converting glucose to sorbitol at the expense of NADPH -a cofactor for generation of reduced glutathione. AR activity, levels of sorbitol and fructose, as well as the NADH/NAD þ ratio, have all been shown to be significantly elevated in [19, 20] . A hyperactivated polyol pathway also correlates with decreased cardiac sympathetic nervous function [21] . Most of the currently available data on AR inhibition have been somewhat focused on diabetic neuropathy and vasculopathy [22, 23] . Recent evidence has shown implications of the action of AR inhibitors on heart function, including an increase in left ventricular ejection fraction independent of blood pressure and insulin [24] . Nevertheless, the effects of AR inhibitors on cardiomyocyte function still remain poorly understood. Our present study is the first report to show beneficial effects of an AR inhibitor on cardiomyocyte contractile function in diabetic obesity. Although the precise mechanism of action behind the AR inhibitorinduced beneficial effects on cardiomyocyte contractile function is not fully clear, several speculations may be AR inhibitor benefits heart function via Sir2 Dong and Ren 2143 made based on findings from our current study as well as others [23] .
Our data revealed that fidarestat antagonized elevated superoxide generation in db/db mouse myocytes, consistent with recent reports of the antioxidant property of AR inhibitors. Obrosova and colleagues [22, 23] reported that AR inhibitors attenuate oxidative as well as nitrosative stress in diabetic retina and nerves, as well as counteracting superoxide formation in diabetic or hyperglycemic aorta and endothelial cells. It is thus plausible to consider an antioxidative role in fidarestat-elicited beneficial effects on diabetic cardiomyocyte dysfunction. In our current study, increased phosphorylated IkB to IkB ratio depicts higher activity of NF-kB, a transcription factor activated by reactive oxygen species [25] . Activation of the NF-kB signaling cascade may result in degradation of IkB, allowing nuclear translocation of NF-kB [26] . Our observation that fidarestat nullified the activation of NFkB, shown as increased ratio between phosphorylated IkB and IkB, in db/db mice also supports its potential antioxidant property. Whether fidarestat participates directly in the regulation of nuclear translocation of NF-kB deserves further study.
Another potential mechanism of action behind fidarestatelicited cardioprotection may be associated with regulation of Na þ , K þ -ATPase. Activity of the Na pump has been shown to be depressed and enhanced by diabetes and AR inhibition, respectively [27, 28] , indicating a possible role of Na þ ,K þ -ATPase in fidarestatelicited cardioprotection against diabetes and/or obesity. Although db/db mice displayed mild systolic hypertension, measured by the semi-automated amplified tail-cuff device, little direct evidence is available to indicate that the AR inhibitor fidarestat can modulate blood pressure and subsequently affect cardiomyocyte function through blood pressure regulation. It is worth mentioning that blood pressure readings obtained from the tail-cuff device are highly correlated with those readings measured by intra-arterial methods [29] .
It should be mentioned that the 1-h in-vitro fidarestat incubation used in our experimental setting may not permanently overcome the phenotypic changes of longterm insulin resistance and diabetes. The beneficial effects of fidarestat on cardiomyocyte function in db/db mice observed in our current study are likely due to the immediate antioxidant property of fidarestat, supported by our dihydroethidium fluorescent microscopic study. It is possible that the acute inhibition of AR and the polyol pathway may alter glucose metabolism in db/db mouse cardiomyocytes, leading to an overall reduction in oxidative stress. Our earlier study revealed that the acute in-vitro inhibition of protein kinase C may temporarily reverse the diabetic cardiomyopathy phenotype in chronically type 1 diabetic mice [30] , supporting the notion that acute inhibition of crucial enzymatic pathways involved in the pathogenesis of diabetic complications (such as polyol and protein kinase C) may transiently reverse the phenotype of diabetic cardiomyocyte dysfunction. The beneficial effect of in-vitro fidarestat treatment was supported by data from a clinical study where 279 diabetic patients were treated with fidarestat for 52 weeks. It was found that fidarestat significantly improved subjective symptoms and electrophysiological measures in diabetics following this long-term treatment [31] . Nonetheless, further study is warranted to elucidate the precise mechanism(s) of action behind the fidarestat-elicited beneficial effect on cardiac contractile function in diseased states.
Perhaps one of the most interesting results from our study is that the fidarestat-induced cardioprotection may be nullified by the silent information regulator 2 (Sir2) inhibitor splitomicin. Sir2 is an NAD-dependent histone AR inhibitor benefits heart function via Sir2 Dong and Ren 2145 deacetylase [13, 14] associated with lifespan extension [32] . Besides its effect on life span, Sir2 may promote fat and glucose mobilization [33] . Enhanced Sir2 levels in pancreatic b-cells have been shown to improve glucose tolerance and enhance insulin secretion [33] . SIRT1, the Sir2 homolog, was found to induce gluconeogenic genes and hepatic glucose output through the transcriptional coactivator PGC-1a [34] . To date, no report has been seen regarding the role of Sir2 or SIRT1 molecules in cardiac contractile function. Nonetheless, Sir2 inhibitors may promote cell death, consistent with the notion that Sir2 gene transfer protects myocytes against apoptosis, leading to modest cardiac hypertrophy [15, 16] . Developmentally, Sir2 contributes to early embryogenesis as well as cardiogenesis and neurogenesis [35] . In our study, fidarestat inhibited activation of NFkB in db/db mice, which was abolished by the Sir2 inhibitor splitomicin. This observation indicates a possible effect of Sir2 on nuclear translocation of NFkB, which may underline a role of Sir2 in fidarestat-induced cardioprotection. The permissive role of Sir2 in fidarestat-elicited cardioprotection against cardiomyocyte dysfunction is further supported by our finding of reduced protein expression of Sir2 in db/db diabetic obese mouse hearts. It is worth mentioning that certain mechanical effects of fidarestat (such as prolonged TR 90 and intracellular Ca 2þ decay) were not affected by splitomicin, suggesting that other mechanism(s) may also contribute to the fidarestatelicited cardioprotective property in db/db mouse hearts.
In conclusion, our study demonstrated compromised cardiomyocyte contractile function in db/db diabetic obese mice. The contractile aberrations in db/db myocytes were paralleled by superoxide anion generation and were significantly improved by fidarestat. The Sir2 pathway may be involved in the beneficial effect of fidarestat, although other mechanisms should not be ruled out at this point. Although the use of AR inhibitors in the treatment of diabetic complications is still in its infancy, our results should shed some light on designing new therapeutic strategies against diabetes and/or obesityassociated cardiac complications.
